Coastline Trust Co Invests $59,000 in VanEck Biotech ETF (NASDAQ:BBH)

Coastline Trust Co bought a new stake in VanEck Biotech ETF (NASDAQ:BBH) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 330 shares of the company’s stock, valued at approximately $59,000.

A number of other large investors have also added to or reduced their stakes in BBH. Mather Group LLC. bought a new stake in shares of VanEck Biotech ETF in the 2nd quarter worth approximately $46,000. Truist Financial Corp raised its position in VanEck Biotech ETF by 3.8% in the 2nd quarter. Truist Financial Corp now owns 2,703 shares of the company’s stock worth $455,000 after purchasing an additional 100 shares during the period. Hyman Charles D bought a new stake in VanEck Biotech ETF in the second quarter worth $202,000. Northwestern Mutual Wealth Management Co. boosted its position in VanEck Biotech ETF by 5.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 24,324 shares of the company’s stock valued at $4,096,000 after buying an additional 1,334 shares during the period. Finally, Atlas Capital Advisors LLC bought a new position in shares of VanEck Biotech ETF during the second quarter valued at about $960,000. Hedge funds and other institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Price Performance

NASDAQ BBH opened at $157.91 on Friday. The stock has a 50-day moving average of $174.98 and a 200-day moving average of $173.14. VanEck Biotech ETF has a 1-year low of $148.52 and a 1-year high of $183.64.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.